5 completed, 1 active not recruiting, 1 terminated, 1 unknown. 9 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Lymphoma, Malignant: new trials by email Literature Review of Lymphoma, Malignant trials Research Report on Lymphoma, Malignant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor TAK-659 - Lymphoma, Malignant, Advanced Solid Neoplasms | Phase 1 | Withdrawn | Calithera Biosciences, Inc | 2018-02-28 | 2023-02-08 | |
| Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Fludarabine, Busulfan, Rabbit ATG - Leukemia, Lymphoid, Leukemia, Myeloid | Phase 1 | Completed | Dartmouth-Hitchcock Medical Center | 20 | 2016-09-06 | 2023-10-18 |
| DS-3201b in Participants With Lymphomas DS-3201b - Lymphoma, Malignant, Non-hodgkin Lymphoma | Phase 1 | Active not recruiting | Daiichi Sankyo Co., Ltd. | 100 | 2016-03-31 | 2026-04-28 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors ASN002 Dose Escalation, ASN002 RD - Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell | Phase 1 / Phase 2 | Terminated | Asana BioSciences | 51 | 2015-05-01 | 2023-06-07 |
| Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics 18F-Al-NOTA-PRGD2 PET/CT - Tumors, Carcinoma, Bronchogenic | Phase 1 | Unknown | Wuxi No. 4 People's Hospital | 200 | 2012-01-01 | 2017-03-10 |
| A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma Enzastaurin - Solid Tumor, Lymphoma, Malignant | Phase 1 | Completed | Eli Lilly and Company | 26 | 2011-11-01 | 2020-10-12 |
| A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin warfarin, enzastaurin - Solid Tumor, Lymphoma, Malignant | Phase 1 | Completed | Eli Lilly and Company | 13 | 2011-08-01 | 2020-07-01 |
| A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies SB1518 - Lymphoma, Malignant, Hodgkin's Lymphoma | Phase 1 | Completed | S*BIO | 35 | 2008-07-01 | 2012-04-20 |
| Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma E7820 - Neoplasms, Lymphoma, Malignant | Phase 1 | Completed | Eisai Inc. | 37 | 2004-01-01 | 2014-12-23 |
Lymphoma (9) · Lymphoma, B-Cell (3) · Neoplasms (3) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Non-Hodgkin (2) · Lymphoma, T-Cell, Peripheral (2) · Primary Myelofibrosis (2) · Breast Neoplasms (1) · Carcinoma, Bronchogenic (1) · Head and Neck Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Lymphoid (1) · Leukemia, Myeloid (1) · Leukemia-Lymphoma, Adult T-Cell (1)
Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoproliferative Disorders (9) · Neoplasms by Histologic Type (9) · Neoplasms (6) · Hematologic Diseases (3) · Leukemia (3) · Bone Marrow Diseases (2) · Leukemia, Lymphoid (2) · Lymphoma, T-Cell (2) · Myeloproliferative Disorders (2) · Blood Protein Disorders (1) · Breast Diseases (1)
enzastaurin (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · Busulfan (1) · Methotrexate (1) · N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide (1) · TAK-659 (1) · Warfarin (1) · fludarabine (1) · thymoglobulin (1)
Eli Lilly and Company (2) · Asana BioSciences (1) · Calithera Biosciences, Inc (1) · Daiichi Sankyo Co., Ltd. (1) · Dartmouth-Hitchcock Medical Center (1) · Eisai Inc. (1) · S*BIO (1) · Wuxi No. 4 People's Hospital (1)
United States (6) · China (2) · Argentina (1) · France (1) · Japan (1)
Anas Younes, M.D. (1) · Jantien Wanders, M.D. (1) · Kenneth Meehan, MD (1) · Niranjan Rao, PhD (1) · Weixing Wan, Professor (1)
PMID 16818691, PMID 18077538, PMID 22965964, PMID 26942463, PMID 38967722, PMID 39486432, PMID 41150706, PMID 41258689